SINGAPORE: NSG BioLabs, Singapore’s largest provider of biotech co-working laboratory and office space, announces a new partnership with Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world.
The partnership aims to support biotech startups by providing needed resources such as product and applications expertise and its networks to advance startup research and development (R&D).
With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with local and international partners, suppliers, and industry experts, NSG BioLabs has helped over 40 companies as residents.
The company’s residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones. The startup residents alone have successfully raised nearly US$400 million in funding and supported hundreds of jobs.
“We are thrilled to announce our strategic partnership with Eppendorf, a leader in life sciences equipment and services. This collaboration will provide our residents with exclusive access to Eppendorf’s cutting-edge equipment, consumables, and services, empowering them to accelerate their research and scale their innovations,” said NSG BioLabs Founder and CEO, Daphne Teo.
“Eppendorf is proud to engage in a partnership with NSG Biolabs, affirming its shared vision for supporting innovators in creating impactful biotech solutions.
“Being part of this scientific community is crucial and this collaboration will be the catalyst for transformative breakthroughs in Singapore and beyond,” said Eppendorf Southeast Asia Managing Director, Surendran Krishnamurthi.
Since its inception, NSG BioLabs has been supporting biotech startups and multinational companies by providing BSL-2 certified private and shared laboratory spaces and offices, equipment, as well as privileged access with service providers and suppliers, and community engagement.
After its first site opening in November 2019, NSG BioLabs expanded with its second site in August 2021, and recently in 2023 with its third site. Now, with three sites totalling 35,000 square feet located in the heart of Singapore’s R&D ecosystem, NSG BioLabs cements its space as a key hub for biotech innovation.
As one of the largest private biotech incubators in the region, coupled with its strong partnerships and strategic investors, such as Celadon Partners and ClavystBio, a life sciences investor set up by Temasek, NSG BioLabs is poised to enhance its value-add offerings of infrastructure, services, and networks for its growing community.
